deaths from tirzepatide AHA 2024 - lowers the risk of worsening heart failure and CVD death for obese adults Weight-loss drug tirzepatide may lower

They do not center on the absence of side effects or risk information

Randomized Trials & Clinical Interventions These are more limited so far, but growing

In the STEP UP trial, participants achieved average weight loss of approximately 20.7% after 72 weeks, with more than one-third losing at least 25% of their starting body weight

For the children that can afford it, the GLP-1 agonists liraglutide and semaglutide are now approved in the USA and Europe for the treatment of obesity in adolescents, as and adjunct to lifestyle interventions

In fact, taking it 30 minutes before a meal can enhance its effectiveness as its already in your system when you start eating

Evitar temperaturas sostenidas superiores a 25C